Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3.47 | 1.70 | 3.13 | 1.80 | 2.49 | 2.56 | 3.23 | 1.52 | 1.46 | 2.42 | 0.00 | 0.00 |
| Expenses | 4.64 | 3.44 | 2.87 | 2.58 | 3.32 | 4.08 | 4.14 | 2.63 | 4.89 | 5.42 | 7.06 | 0.84 |
| Operating Profit | -1.17 | -1.74 | 0.26 | -0.78 | -0.83 | -1.52 | -0.91 | -1.11 | -3.43 | -3.00 | -7.06 | -0.84 |
| OPM % | -33.72% | -102.35% | 8.31% | -43.33% | -33.33% | -59.38% | -28.17% | -73.03% | -234.93% | -123.97% | ||
| Other Income | 0.08 | 0.02 | 0.10 | 0.07 | 0.01 | 0.12 | 0.24 | 0.00 | 0.19 | 0.09 | 0.03 | 0.04 |
| Interest | 0.32 | 0.30 | 0.28 | 0.28 | 0.25 | 0.22 | 0.21 | 0.19 | 0.18 | 0.18 | 0.55 | 0.34 |
| Depreciation | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.19 | 0.18 | 0.18 | 0.20 | 0.19 | 0.19 | 0.19 |
| Profit before tax | -1.59 | -2.20 | -0.10 | -1.17 | -1.25 | -1.81 | -1.06 | -1.48 | -3.62 | -3.28 | -7.77 | -1.33 |
| Tax % | 27.04% | -25.91% | -190.00% | -26.50% | -22.40% | -26.52% | 40.57% | -12.84% | -28.45% | -29.27% | -24.58% | -25.56% |
| Net Profit | -2.02 | -1.63 | 0.09 | -0.86 | -0.97 | -1.32 | -1.50 | -1.29 | -2.59 | -2.32 | -5.86 | -0.99 |
| EPS in Rs | -0.55 | -0.44 | 0.02 | -0.23 | -0.26 | -0.36 | -0.41 | -0.21 | -0.42 | -0.38 | -0.95 | -0.16 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15 | 24 | 29 | 31 | 23 | 1 | 0 | 1 | 10 | 10 | 5 | 4 |
| Expenses | 13 | 21 | 24 | 30 | 28 | 3 | 2 | 5 | 13 | 14 | 20 | 18 |
| Operating Profit | 3 | 3 | 5 | 1 | -5 | -2 | -1 | -4 | -3 | -4 | -15 | -14 |
| OPM % | 17% | 13% | 18% | 4.0% | -21% | -136% | -326% | -432% | -33% | -41% | -271% | -369% |
| Other Income | 0 | 0 | 0 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 1 | 3 | 1 | -4 | -4 | -3 | -6 | -5 | -5 | -16 | -16 |
| Tax % | 8% | -2% | 23% | 18% | -7% | -47% | -66% | -4% | -13% | -12% | -25% | |
| Net Profit | 1 | 1 | 2 | 1 | -4 | -2 | -1 | -6 | -5 | -5 | -12 | -12 |
| EPS in Rs | 0.06 | 0.47 | 0.75 | 0.31 | -1.21 | -0.55 | -0.24 | -1.54 | -1.23 | -1.26 | -1.96 | -1.91 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | -10% | 34% | 75% | -60% | ||
| Compounded Profit Growth | % | % | % | -132% | ||
| Stock Price CAGR | -11% | -7% | -29% | -34% | ||
| Return on Equity | -9% | -14% | -17% | -29% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 12 | 12 |
| Reserves | 5 | 6 | 11 | 26 | 30 | 24 | 25 | 28 | 29 | 31 | 33 | 24 |
| Borrowings | 4 | 8 | 11 | 11 | 11 | 15 | 11 | 13 | 10 | 8 | 7 | 10 |
| Other Liabilities | 8 | 7 | 14 | 10 | 6 | 6 | 9 | 8 | 9 | 10 | 7 | 9 |
| Total Liabilities | 23 | 26 | 42 | 53 | 53 | 51 | 53 | 56 | 56 | 58 | 60 | 55 |
| Fixed Assets | 11 | 10 | 13 | 18 | 21 | 21 | 20 | 19 | 20 | 19 | 19 | 18 |
| CWIP | 0 | 0 | 2 | 7 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 11 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 12 | 16 | 26 | 28 | 24 | 22 | 24 | 27 | 27 | 29 | 31 | 26 |
| Total Assets | 23 | 26 | 42 | 53 | 53 | 51 | 53 | 56 | 56 | 58 | 60 | 55 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -4 | -2 | 3 | -5 | 3 | 1 | -7 | -1 | -2 | -5 | -7 | -4 |
| Cash from Investing Activity | -0 | -0 | -4 | -11 | -6 | -2 | -0 | -0 | -1 | -1 | -0 | -1 |
| Cash from Financing Activity | 4 | 3 | 6 | 11 | 1 | 0 | 7 | 1 | 3 | 6 | 8 | 5 |
| Net Cash Flow | 0 | 0 | 5 | -4 | -1 | -1 | -0 | -0 | 0 | -0 | 1 | -1 |
| Free Cash Flow | -4 | -3 | -1 | -15 | -2 | -1 | -7 | -1 | -3 | -6 | -7 | -5 |
| CFO/OP | -131% | -89% | 84% | -86% | 299% | -17% | 390% | 78% | 64% | 149% | 163% | 30% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 300 | 231 | 136 | 137 | 98 | 165 | 624 | 9,789 | 4,106 | 515 | 505 | 22 |
| Inventory Days | 10 | 97 | 185 | 250 | 162 | 148 | 4,840 | 9,204 | 991 | 279 | 359 | 770 |
| Days Payable | 359 | 236 | 293 | 209 | 76 | 79 | 2,555 | 5,297 | 1,007 | 304 | 244 | 443 |
| Cash Conversion Cycle | -50 | 92 | 27 | 178 | 184 | 234 | 2,909 | 13,696 | 4,089 | 490 | 620 | 349 |
| Working Capital Days | -8 | 206 | 12 | 137 | 137 | 81 | 1,681 | 10,154 | 3,460 | 318 | 440 | -95 |
| ROCE % | 14% | 10% | 9% | 12% | 6% | -5% | -5% | -4% | -10% | -8% | -9% | -30% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 29.51% | 27.81% | 27.81% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% |
| DIIs | 0.03% | 0.03% | 0.03% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| Public | 70.46% | 72.16% | 72.16% | 78.79% | 78.79% | 78.79% | 78.78% | 78.78% | 78.78% | 78.78% | 78.80% | 78.80% |
| No. of Shareholders | 14,250 | 13,908 | 14,015 | 13,882 | 13,913 | 14,086 | 14,158 | 14,061 | 14,012 | 14,080 | 14,154 | 14,154 |
Fundamentals
Market Cap₹ 42.7 Cr.
Current Price₹ 6.93
Book Value₹ 5.92
ROCE-30.3 %
ROE-29.5 %
Dividend Yield0.00 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)-60%
Compounded Profit Growth (TTM)-132%
Standalone figures.
Valuation
Market capRs 38 Cr
Enterprise valueRs 48 Cr
Price to book1.05x
Price to sales7.08x
EV / sales8.91x
Earnings yield-30.76%
P/B, 3-year average1.35x
P/B, 5-year average1.13x
Profitability
Operating margin (excl. other income)-270.74%
Operating margin (incl. other income)-264.81%
EBITDA margin-258.89%
Pre-tax margin-296.30%
Net profit margin-217.78%
ROE-29.46%
ROCE-30.33%
ROA-20.91%
ROE, 3-year average-17.33%
ROCE, 3-year average-15.72%
ROA, 3-year average-12.23%
ROE, 5-year average-14.06%
ROCE, 5-year average-12.10%
ROA, 5-year average-9.69%
ROIC (approx.)-23.78%
Tax rate25.33%
Other income / net worth0.88%
Growth
Sales growth (latest year)-44.84%
Sales CAGR, 3 years75.44%
Sales CAGR, 5 years33.57%
Per share
EPS (TTM)Rs -1.91
EPS (latest quarter)Rs -0.16
EPS, 3-year averageRs -0.86
EPS, 5-year averageRs -0.87
Book value per shareRs 5.92
Sales per shareRs 0.88
Cash flow per shareRs -0.71
Free cash flow per shareRs -0.81
Efficiency
Asset turnover0.10x
Fixed asset turnover0.30x
Inventory turnover0.47x
Inventory days770 days
Debtor days22 days
Debtors turnover16.88x
Creditor days443 days
Cash conversion cycle349 days
Working capital days-95 days
Leverage
Total debtRs 10 Cr
Cash and bankRs 0 Cr
Net debtRs 10 Cr
Debt to equity0.27x
Interest coverage-11.80x
Owners' fund to total sources66.16%
Debt to assets18.12%
Cash flow
Cash from Operating Activity (latest year)Rs -4 Cr
Cash from Investing Activity (latest year)Rs -1 Cr
Cash from Financing Activity (latest year)Rs 5 Cr
Net Cash Flow (latest year)Rs -1 Cr
Free cash flow (latest year)Rs -5 Cr
FCFE (approx.: FCF + change in debt)Rs -2 Cr
Statement figures
Net sales (TTM)Rs 5 Cr
Net sales (latest year)Rs 5 Cr
Operating profit excl. other income (latest year)Rs -15 Cr
Operating profit (latest quarter)Rs -1 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs -14 Cr
PBDT (TTM)Rs -15 Cr
Profit before tax (TTM)Rs -16 Cr
Tax (latest year)Rs -4 Cr
Net profit (TTM)Rs -12 Cr
Net profit (latest year)Rs -12 Cr
Net profit (latest quarter)Rs -1 Cr
Depreciation (TTM)Rs 1 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 5 Cr
Total expenditure (latest year)Rs 20 Cr
Total income (latest year)Rs 6 Cr
Share capitalRs 12 Cr
ReservesRs 24 Cr
Shareholders' fundsRs 36 Cr
Total assetsRs 55 Cr
Net blockRs 18 Cr
Capital work in progressRs 11 Cr
InvestmentsRs 0 Cr
ReceivablesRs 0 Cr
InventoryRs 11 Cr
Other liabilitiesRs 9 Cr
Shares outstanding (crore)6.16
Ownership
Promoter holding21.19% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/B 1.05 is at the 3th percentile (median 1.90).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 524711 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -5.6% | -2.8% | -2.8 pts |
| 1 month | +3.2% | -6.8% | +9.9 pts |
| 3 months | -13.3% | -7.6% | -5.7 pts |
| 3 years | -64.5% | +14.2% | -78.7 pts |
| 5 years | -31.9% | +27.9% | -59.8 pts |
Red flags
F-score 1 of 8| explain | Share dilution Share count up 67% in a year, 67% in three |
| explain | Debt up, profit down Borrowings up 35% while net profit fell in 2026 |
| look | Inventory outrunning sales Inventory grew 34% vs sales -45% in 2026 |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹0 Cr -100.0% vs Jun 2025.
Net loss ₹1 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd (524711) has a market capitalisation of Rs 42.7 Cr. at the 2026-10-01 close.
What were Vista Pharmaceuticals Ltd's latest quarterly results?
In the Jun 2026 quarter, Vista Pharmaceuticals Ltd sales was Rs 0 Cr (-100.0% vs Jun 2025) with a net loss of Rs 1 Cr.